Kate Merry of PEM has appointed Metis Partners to support the marketing and sale of intellectual property (“IP”) assets relating to Enigma Diagnostics Limited (in Liquidation) (“Enigma Diagnostics” or “the Company”).
IP ASSET HIGHLIGHTS
- Global Market Opportunity
- International Patent Protection
- Extensive Trade Mark Portfolio
- Patent Licensing Opportunities
- Over £140 Million Invested
- Special Relationship with Ministry of Defence
This is a unique opportunity to purchase the IP assets behind cutting-edge technology including an international patent portfolio, software, registered designs, website & domain names and significant organisational knowledge.
All offers and requests for more information should be submitted by email directly to Morven Fraser (email@example.com). The deadline for offers is set at Thursday 11th May 2017 at noon.
Enigma Diagnostics was set up in 2004 in order to bring innovative molecular diagnostic technology to the commercial market, following initial development of the technology at the UK’s Ministry of Defence’s Science Technology Laboratory (“DSTL”).
The Enigma Diagnostics’s technology provides easy and fast molecular diagnostics through its internationally-patented Enigma Minilab device, using an innovative application of Polymerase Chain Reaction (“PCR”) technology. This fully automated molecular test platform can be used in the clinical laboratory or for diagnostics in hospitals, clinics, doctor’s surgeries and pharmacies.
To date, the Company has spent over £140 million on developing their technology, and also held a licence from DSTL.
Enigma Diagnostics could offer opportunities for companies in the diagnostics industry, the healthcare industry, defence and animal health sectors as well as drug and pharmacology sectors.
The major capabilities of the Enigma Minilab device include: accuracy, speed, portability, ease of operation, and the ability to multiplex. Moreover, it can be fully operated by technicians with minimal training.
The Enigma MiniLab device has undergone trials with selected NHS hospitals, showing an accuracy of above 90% in the detection of specific pathogens, and had also undergone trials with hospitals in Europe and China.
The Company’s technology relies on a patented process comprising the following elements:
- A unique heating and cooling thermal cycle process using an Electrically Conductive Polymer
- A PCR instrument which includes an advanced optics component that can simultaneously quantify multiple separate targets in a single PCR reaction
- An automated sample preparation process based on magnetic bead transfer
IP ASSETS FOR SALE
- Granted patents and patent applications
- Registered and unregistered trade marks
- Goodwill in in the brand and reputation
- Rights in the registered designs
- Website content and domain names
- Organisational knowledge